Steve Wolpe

Steve Wolpe has a long and varied work experience in biotechnology. Steve began their career in 1982 as a Postdoctoral Fellow in Jennie Mather's lab at the Population Council, where they studied the interactions between Sertoli and myoid cells and developed some monoclonal antibodies that affected their interactions. Steve then moved to Tony Cerami's lab at Rockefeller University, where they made the first monoclonal to TNF, which was used to demonstrate the role of TNF in sepsis. In 1988, they became a Staff Scientist at Genetics Institute, where they led the MIP1a project (published in Nature) and later started a project on intestinal stem cells. In 1993, they became the Director at Pro-Neuron Inc. (now Wellstat), where their lab served as a resource lab for all Wellstat companies. Steve also became the Sr. Dir. Cell Mol. Biol. at Wellstat Therapeutics, where they directed research programs in diabetes, inflammatory disease, cancer and stem cell biology and worked closely with the CEO on licensing, intellectual property and business development issues. In 2010, they became an Independent Biotechnology Consultant for Startup Companies. From 2016 to 2018, they were an Entrepreneur-in-Residence at both BioHealth Innovation, Inc. and the NIH SEED Office. Finally, in 2018 they became the VP Preclinical Development at Khloris Biosciences.

Steve Wolpe began their educational career in 1972 when they attended Amherst College, where they earned a B.A. in Biology in 1976. Steve then attended the University of Pennsylvania from 1977 to 1985, where they earned a Ph.D. in Anatomy and Immunology. From 1982 to 1988, they completed a Postdoc at The Rockefeller University.